Assessing oncologic benefit in clinical trials of immunotherapy agents

Annals of Oncology

Volumn 21, Issue 10, 2010, Pages 1944-1951

  Hales, R K ^a   Banchereau, J ^b   Ribas, A ^c   Tarhini, A A ^d   Weber, J S ^e   Fox, B A ^f   Drake, C G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cancer; Clinical benefit; Immunotherapy; Mixed response; RECIST; Response evaluation

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CD28 ANTIGEN; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DNA VACCINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HISTONE DEACETYLASE INHIBITOR; IPILIMUMAB; MITOXANTRONE; PEPTIDE VACCINE; PREDNISONE; PROTEIN KINASE INHIBITOR; SORAFENIB; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; TRASTUZUMAB; VIRUS VACCINE;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL TRIAL; COLORECTAL CANCER; DOWN REGULATION; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS POTENTIAL; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE ACTIVATION; TUMOR FLARE; TUMOR VOLUME;

EID: 77954916754     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq048     Document Type: Review

References (44)

1. Williams G, Pazdur R, Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat 2004; 14: 5-21.
2. Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 1985; 69: 1155-1159.
3. US Food and Drug Administration. CFR-Code of Federal Regulations Title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch 2.cfm?CFRPart=314. (6 August 2009, date last accessed).
4. Dagher R, Cohen M, Williams G et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002; 8: 3034-3038.
5. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
6. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
7. Pazdur R. Response rates, survival, and chemotherapy trials. J Natl Cancer Inst 2000; 92: 1552-1553.
8. Husband JE, Schwartz LH, Spencer J et al. Evaluation of the response to treatment of solid tumours-a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004; 90: 2256-2260.
9. Chen TT, Chute JP, Feigal E et al. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1601-1607.
10. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356: 373-378.
11. Ratain MJ, Eckhardt SG. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 2004; 22: 4442-4445.
12. Korn EL, Arbuck SG, Pluda JM et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19: 265-272.
13. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
14. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
15. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008; 8: 1.
16. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227-238.
17. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297-339.
18. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19: 565-594.
19. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
20. Wilcox RA, Flies DB, Zhu G et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002; 109: 651-659.
21. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007; 12: 864-872.
22. Weber JS. The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res 2006; 16: 379-383.
23. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-2627.
24. Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005; 23: 8968-8977.
25. Ribas A, Hanson DC, Noe DA et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007; 12: 873-883.
26. Hamid O, Urba WJ, Yellin MJ et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma [poster]. Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, 1-5 June 2007. Abstract 8525.
27. Finke LH, Wentworth K, Blumenstein B et al. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007; 25 (Suppl 2): B97-B109.
28. Goffin J, Baral S, Tu D et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res 2005; 11: 5928-5934.
29. Anderson KC, Hannah AL, Pazdur R, Farrell AT. A strategic framework for novel drug development in multiple myeloma. Br J Haematol 2007; 138: 153-159.
30. Comin-Anduix B, Lee Y, Jalil J et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 2008; 6: 22.
31. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358: 1409-1411.
32. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
33. Freidlin B, Korn EL, Hunsberger S et al. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol 2007; 25: 2122-2126.
34. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-2513.
35. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 1654-1663.
36. Smith MM, Thompson JE, Castillo M et al. MR of recurrent high-grade astrocytomas after intralesional immunotherapy. AJNR Am J Neuroradiol 1996; 17: 1065-1071.
37. Hodi FS, Hoos A, Ibrahim R et al. Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody [oral presentation]. Presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, 30 May to 3 June 2008. Abstract 3008.
38. Korn EL, Liu PY, Lee SJ et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
39. Ratain MJ. Phase II oncology trials: let's be positive. Clin Cancer Res 2005; 11: 5661-5662.
40. Rubinstein L, Crowley J, Ivy P et al. Randomized phase II designs. Clin Cancer Res 2009; 15: 1883-1890.
41. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002; 20: 4478-4484.
42. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512.
43. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
44. Cannistra SA. Phase II trials in journal of clinical oncology. J Clin Oncol 2009; 27: 3073-3076.